Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Current Oncology Reports|June 14, 2018
Toxicity of Cancer Therapies in Older PatientsOlivia Le Saux, Claire Falandry
Current Oncology Reports|February 8, 2018
Is There an Age Threshold for Holding Off on Testing Novel Therapies?Olivia Le Saux, Claire Falandry
Clinical Drug Investigation|March 7, 2016
First-Line Treatments for Poor-Prognosis Metastatic Renal Cell Carcinoma: Experts' Prescribing Practices and Systematic Literature ReviewOlivia Le Saux, Gilles Freyer, Sylvie Négrier
Seminars in Cancer Biology|September 15, 2020
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancerOlivia Le Saux, Isabelle Ray-Coquard, S Intidhar Labidi-Galy
International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group|October 9, 2018
Long-term survival in patients with epithelial ovarian cancer following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)Olivia Le Saux, Evelyne Decullier, Gilles Freyer, et al.
Clinical Interventions in Aging|October 14, 2017
Assessing capacity to consent for research in cognitively impaired older patientsThomas Gilbert, Antoine Bosquet, Catherine Thomas-Antérion, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 23, 2025
Controversies in the management of serous tubal intra-epithelial carcinoma lesions of the fallopian tubeOlivia Le Saux, Iain McNeish, Maurizio D'Incalci, et al.
Clinical Epidemiology|November 26, 2015
Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in FranceOlivia Le Saux, Aliki Taylor, Victoria Chia, et al.
The Oncologist|February 3, 2019
Changes in the Use of Comprehensive Geriatric Assessment in Clinical Trials for Older Patients with Cancer over TimeOlivia Le Saux, Claire Falandry, Hui K Gan, et al.
Current Oncology Reports|November 9, 2021
Treatment Perspectives for Ovarian Cancer in Europe and the United States: Initial Therapy and Platinum-Sensitive Recurrence after PARP Inhibitors or Bevacizumab TherapyAlexandra Lainé, Travis T Sims, Olivia Le Saux, et al.
Pageof 5